OTCMKTS:TRPXD

Therapix Biosciences Stock Forecast, Price & News

$9.08
+0.57 (+6.70 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.70
Now: $9.08
$9.35
50-Day Range
$5.98
MA: $7.59
$9.19
52-Week Range
$2.75
Now: $9.08
$22.40
Volume57,436 shs
Average Volume1,852 shs
Market Capitalization$454,000.00
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:TRPXD
CUSIPN/A
CIKN/A
Phone972 3 616 7055
Employees8
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.28 per share

Profitability

Miscellaneous

Market Cap$454,000.00
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1843rd out of 2,011 stocks

Pharmaceutical Preparations Industry

735th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$9.08
+0.57 (+6.70 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TRPXD News and Ratings via Email

Sign-up to receive the latest news and ratings for TRPXD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Therapix Biosciences (OTCMKTS:TRPXD) Frequently Asked Questions

What stocks does MarketBeat like better than Therapix Biosciences?

Wall Street analysts have given Therapix Biosciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Therapix Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Therapix Biosciences' key executives?

Therapix Biosciences' management team includes the following people:
  • Mr. Oz Adler CPA, Chief Financial Officer (Age 33, Pay $220k)
  • Dr. Adi Zuloff-Shani, Chief Technologies Officer (Age 50, Pay $237k)
  • Mr. Amitay Weiss, CEO & Director (Age 58)

Who are some of Therapix Biosciences' key competitors?

What is Therapix Biosciences' stock symbol?

Therapix Biosciences trades on the OTCMKTS under the ticker symbol "TRPXD."

How do I buy shares of Therapix Biosciences?

Shares of TRPXD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Therapix Biosciences' stock price today?

One share of TRPXD stock can currently be purchased for approximately $9.08.

How much money does Therapix Biosciences make?

Therapix Biosciences has a market capitalization of $454,000.00.

How many employees does Therapix Biosciences have?

Therapix Biosciences employs 8 workers across the globe.

What is Therapix Biosciences' official website?

The official website for Therapix Biosciences is therapixbio.com.

How can I contact Therapix Biosciences?

The company can be reached via phone at 972 3 616 7055.


This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.